BiOptic hits a new high in revenue in the first 10-month of 2022

The world's largest medical tradeshow, MEDICA, in Dusseldorf Germany will be held from November 14th to 17th. BiOptic will participate in the exhibition for the first time after the COVID-19 epidemic. Chairman Eric Tsai said that the company has actively expanded the European market in recent years and the penetration rate continues to increase. This time, with the "open detection platform" as the main axis, producing our core products, Qsep Series Bio-Fragment Analyzer. It will also be used with the Qexp series reagent kits as an example, so that distribution partners can understand the concept of open detection platform, hoping to expand the local market share and the revenue growth.

The portable capillary electrophoresis system, Qsep1-Lite will be exhibit this time. It has both technical and application advantages, and won the affirmation of this year's "Taiwan Excellence Award". Qsep1-Lite adopts an intuitive software analysis interface, which allows all people to perform detection and analysis by themselves, which is very suitable for on-site detection and use to create an exclusive mobile laboratory. Taking shrimp disease detection as an example, many domestic shrimp farmers have adopted this set of solutions.

Among the detection kits, the Qexp-MDx Direct SARS-CoV-2 Detection Kit (CE-IVD), which obtained EU CE-IVD certification in March this year, will be exhibited as well. It is an extraction-free and uses oral samples for detection and analysis.

In recent years, the global biomedical industry has focused on the general health trend, and is optimistic about topics including on-site detection of infectious diseases, preventive medicine, precision medicine, and companion diagnostics. The European Union is the second largest genetic testing market in the world. The core products of BiOptic will be effectively applied in the development and verification process of related products.

BiOptic recently announced that its consolidated revenue in October was 26.3 million yuan, a new monthly high this year, with an annual increase of 19%; the accumulated consolidated revenue in the first 10 months reached 173 million yuan, which not only hit a record high for the same period of the previous year, but almost caught up with last year's Annual level, an annual increase of nearly 35%. In terms of regions, although the proportion of revenue from Europe in the first 10 months was only about 5.4%, the annual growth rate exceeded 20%. Among them, Germany, the host country of this MEDICA, recorded an annual revenue growth of 63%. . Looking forward to the fourth quarter, the benefits of the beneficiary brands continue to show, and the company has entered the peak season for stockpiling of major customers.